MX2021015667A - Metodo de reconstitucion de anamicina liposomica. - Google Patents
Metodo de reconstitucion de anamicina liposomica.Info
- Publication number
- MX2021015667A MX2021015667A MX2021015667A MX2021015667A MX2021015667A MX 2021015667 A MX2021015667 A MX 2021015667A MX 2021015667 A MX2021015667 A MX 2021015667A MX 2021015667 A MX2021015667 A MX 2021015667A MX 2021015667 A MX2021015667 A MX 2021015667A
- Authority
- MX
- Mexico
- Prior art keywords
- reconstitution
- anamicin
- liposomic
- methods
- anamycin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868190P | 2019-06-28 | 2019-06-28 | |
| PCT/US2020/039621 WO2020264161A1 (en) | 2019-06-28 | 2020-06-25 | Method of reconstituting liposomal annamycin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015667A true MX2021015667A (es) | 2022-04-18 |
Family
ID=74061076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015667A MX2021015667A (es) | 2019-06-28 | 2020-06-25 | Metodo de reconstitucion de anamicina liposomica. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12257262B2 (https=) |
| EP (1) | EP3990041B1 (https=) |
| JP (1) | JP7830131B2 (https=) |
| KR (1) | KR20220027941A (https=) |
| CN (2) | CN114728101B (https=) |
| AU (2) | AU2020302784A1 (https=) |
| BR (1) | BR112021026480A2 (https=) |
| CA (1) | CA3144443A1 (https=) |
| ES (1) | ES3049663T3 (https=) |
| IL (1) | IL289433B1 (https=) |
| MX (1) | MX2021015667A (https=) |
| PL (1) | PL3990041T3 (https=) |
| SG (1) | SG11202113005SA (https=) |
| TW (2) | TW202500161A (https=) |
| WO (1) | WO2020264161A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3049663T3 (en) | 2019-06-28 | 2025-12-17 | Univ Texas | Method of reconstituting liposomal annamycin |
| KR20220027969A (ko) | 2019-06-28 | 2022-03-08 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 프리리포솜 아나마이신 동결건조물의 제조 |
| KR20220103992A (ko) * | 2019-11-21 | 2022-07-25 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 리포솜 아나마이신에 의한 폐 표적화 항암 요법 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927571A (en) * | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4863739A (en) | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
| IS1685B (is) * | 1990-12-11 | 1998-02-24 | Bracco International B.V. | Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum |
| US5902604A (en) * | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| WO2001032145A1 (en) * | 1999-10-29 | 2001-05-10 | Board Of Regents, The University Of Texas System | Method of cancer treatment |
| EP2314285B2 (en) * | 2003-02-14 | 2019-09-18 | Children's Hospital & Research Center at Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| PL2544537T3 (pl) * | 2010-03-10 | 2017-10-31 | Cempra Pharmaceuticals Inc | Pozajelitowe preparaty antybiotyków makrolidowych |
| WO2013055874A2 (en) * | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| EP3572071A1 (en) * | 2011-10-21 | 2019-11-27 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
| US8926994B2 (en) | 2011-12-07 | 2015-01-06 | The Methodist Hospital Research Institute | Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| CN107569508A (zh) * | 2016-07-05 | 2018-01-12 | 江苏竞诺择生物医药科技有限公司 | 一种治疗造血系统增殖性疾病的药用组合物 |
| WO2018048752A1 (en) | 2016-09-09 | 2018-03-15 | Irisys, Inc. | Lipsomal anticancer compositions |
| WO2019023873A1 (zh) * | 2017-07-31 | 2019-02-07 | 江苏竞诺择生物医药科技有限公司 | 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物 |
| MA53565A (fr) | 2018-09-04 | 2021-07-14 | Minerva Neurosciences Inc | Procédés d'utilisation d'un composé phénoxypropylamine pour le traitement de la douleur |
| ES3049663T3 (en) | 2019-06-28 | 2025-12-17 | Univ Texas | Method of reconstituting liposomal annamycin |
| KR20220027969A (ko) | 2019-06-28 | 2022-03-08 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 프리리포솜 아나마이신 동결건조물의 제조 |
| KR20220103992A (ko) | 2019-11-21 | 2022-07-25 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 리포솜 아나마이신에 의한 폐 표적화 항암 요법 |
-
2020
- 2020-06-25 ES ES20832031T patent/ES3049663T3/es active Active
- 2020-06-25 WO PCT/US2020/039621 patent/WO2020264161A1/en not_active Ceased
- 2020-06-25 AU AU2020302784A patent/AU2020302784A1/en active Pending
- 2020-06-25 CN CN202080048890.7A patent/CN114728101B/zh active Active
- 2020-06-25 EP EP20832031.7A patent/EP3990041B1/en active Active
- 2020-06-25 MX MX2021015667A patent/MX2021015667A/es unknown
- 2020-06-25 CA CA3144443A patent/CA3144443A1/en active Pending
- 2020-06-25 BR BR112021026480A patent/BR112021026480A2/pt unknown
- 2020-06-25 KR KR1020227000486A patent/KR20220027941A/ko active Pending
- 2020-06-25 CN CN202310738252.3A patent/CN116785242A/zh active Pending
- 2020-06-25 JP JP2021577862A patent/JP7830131B2/ja active Active
- 2020-06-25 SG SG11202113005SA patent/SG11202113005SA/en unknown
- 2020-06-25 PL PL20832031.7T patent/PL3990041T3/pl unknown
- 2020-06-29 TW TW113132623A patent/TW202500161A/zh unknown
- 2020-06-29 TW TW109121840A patent/TWI857086B/zh active
-
2021
- 2021-12-17 US US17/554,553 patent/US12257262B2/en active Active
- 2021-12-27 IL IL289433A patent/IL289433B1/en unknown
-
2023
- 2023-10-05 US US18/481,951 patent/US11980634B2/en active Active
-
2024
- 2024-05-29 AU AU2024203593A patent/AU2024203593B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3990041A1 (en) | 2022-05-04 |
| TW202500161A (zh) | 2025-01-01 |
| EP3990041B1 (en) | 2025-08-06 |
| CN114728101B (zh) | 2023-07-14 |
| CN114728101A (zh) | 2022-07-08 |
| PL3990041T3 (pl) | 2026-02-23 |
| US12257262B2 (en) | 2025-03-25 |
| AU2020302784A1 (en) | 2022-01-20 |
| IL289433A (en) | 2022-02-01 |
| US11980634B2 (en) | 2024-05-14 |
| JP2023523872A (ja) | 2023-06-08 |
| CA3144443A1 (en) | 2020-12-30 |
| WO2020264161A1 (en) | 2020-12-30 |
| JP7830131B2 (ja) | 2026-03-16 |
| SG11202113005SA (en) | 2021-12-30 |
| TW202114704A (zh) | 2021-04-16 |
| BR112021026480A2 (pt) | 2022-02-08 |
| EP3990041A4 (en) | 2023-07-12 |
| US20240024345A1 (en) | 2024-01-25 |
| CN116785242A (zh) | 2023-09-22 |
| KR20220027941A (ko) | 2022-03-08 |
| US20220105116A1 (en) | 2022-04-07 |
| TWI857086B (zh) | 2024-10-01 |
| IL289433B1 (en) | 2026-01-01 |
| AU2024203593B2 (en) | 2025-08-14 |
| ES3049663T3 (en) | 2025-12-17 |
| AU2024203593A1 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY205856A (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| MX2021015667A (es) | Metodo de reconstitucion de anamicina liposomica. | |
| MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
| MX2026000462A (es) | Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de estos | |
| PH12019502341A1 (en) | Compositions and methods involving probiotic molecules | |
| MX2023009681A (es) | Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon. | |
| BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
| ZA202103975B (en) | Methods of treating disease with magl inhibitors | |
| WO2017087827A8 (en) | Method of making recombinant silk and silk-amyloid hybrid proteins using bacteria | |
| CL2020003355A1 (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiple | |
| EP3595634A4 (en) | CONSTRUCTIONS FOR GENE THERAPY AND METHODS FOR THE TREATMENT OF HEARING LOSS | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| WO2021191689A3 (en) | Treatment of inflammatory diseases with peptides and pharmaceutical compositions | |
| JOP20190164B1 (ar) | تركيبات وطرق لعلاج داء فاربر | |
| CY1124679T1 (el) | Μεθοδος μειωσης η απενεργοποιησης του ιικου και μικροβιακου περιεχομενου στις μεθοδους παρασκευης παγκρεατινης | |
| MX2021008865A (es) | Inhibidores de magl para usarse para tratar enfermedades antecedentes. | |
| MX2021015765A (es) | Nuevos antigenos y metodos contra el cancer. | |
| JOP20230034A1 (ar) | مثبطات إفراز البروتين | |
| IL289251A (en) | Methods and compositions for treatment of pancreatic cancer | |
| PH12020551146A1 (en) | Methods for treating farber disease | |
| IL315142A (en) | Methods and compositions for treating hearing loss | |
| EA202190590A1 (ru) | Соединения и способы лечения грибковых инфекций | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| JOP20220068A1 (ar) | بروتينات اندماج nkg2d واستخداماتها | |
| MX2022011027A (es) | Composiciones y metodos para el tratamiento del cancer. |